Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth.

Novo Nordisk said Thursday it will seek federal approval to expand the use of its Ozempic and Rybelsus pills to kids and ...

Novo Nordisk (CPSE:NOVO B) reported strong phase 3 trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The company plans to file for US and EU label expansions to ...

Telangana DCA cracks down on weight-loss drug violations, 75 medical shops face action: Our Bureau, Chennai Friday, April 24, 2026, 11:15 Hrs [IST] The Drugs Control Administratio ...

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

Novo Nordisk (NVO) stock is in focus as the company plans to launch Ozempic pill for children with type 2 diabetes after a ...

PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10-17 years with type ...

A late-stage trial showed that oral semaglutide significantly reduced blood sugar in 10- to 17-year-olds.

Indian pharma companies are betting on Chinese partnerships to bring oral GLP-1 drugs to market, but the window to act is ...

Novo Nordisk’s Phase 3a PIONEER TEENS trial found that oral semaglutide significantly lowered blood sugar in adolescents with type 2 diabetes compared with placebo and was well tolerated. The company ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

The PIONEER TEENS trial compared oral semaglutide at maximum tolerated doses with placebo in adolescents aged 10 to 17 years with T2D.